trending Market Intelligence /marketintelligence/en/news-insights/trending/DAFJkpuG85VLNNfmDzJSHw2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Intellipharmaceutics, Aceto to be delisted from Nasdaq


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


COVID-19 Impact & Recovery: Private Equity

Intellipharmaceutics, Aceto to be delisted from Nasdaq

Intellipharmaceutics International Inc. and Aceto Corp.'s common stocks will be delisted from the Nasdaq Stock Market.

Intellipharmaceutics International was suspended from trading March 21, while Aceto was suspended April 3.

Toronto-based Intellipharmaceutics is engaged in the research, development and commercialization of controlled-release and targeted pharmaceutical products, with a particular focus on opioid abuse deterrence.

Meanwhile, Aceto develops and distributes human health products, pharmaceutical ingredients and performance chemicals. The Port Washington, N.Y.-based company filed for Chapter 11 bankruptcy protection in February.

The delisting will be effective 10 days after Nasdaq files a Form 25 to the Securities and Exchange Commission.